GLOW
GLOW

£49.99

Add to basket This product has multiple variants. The options may be chosen on the product page

GLOW

£49.99

  • UK Stock
  • Secure Payments
  • Discreet UK Delivery

GLOW is a 70mg research blend containing GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg, supplied as a lyophilised material for extracellular-matrix, cell-migration and tissue-remodelling research.

COMPLETE YOUR KIT

Bacteriostatic Water - 3ml
Bacteriostatic Water - 3ml

In stock

£3.99
MOTS-c - 10mg
MOTS-c - 10mg

In stock

£24.99
1 Vial
£49.99
1 Vial
£44.99 Save 10%
3 Vials
£42.49 Save 15%
5 Vials
£39.99 Save 20%

For in vitro laboratory research only.
Not for human or veterinary use. Not for diagnosis, treatment, cure, or prevention of any disease. No dosage, administration, or injection guidance is provided.

GLOW is a 70mg research blend containing GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg. It is supplied as a single lyophilised material for controlled laboratory studies of extracellular-matrix regulation, cell migration and tissue-remodelling pathways.

Research blend only

This material is not supplied as a medicine, treatment, cosmetic, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.

Blend overview

Product typeThree-component research blend
GHK-Cu50mg
BPC-15710mg
TB-50010mg
Total nominal content70mg
FormLyophilised blend

Research context

The GLOW formulation combines three separately named research materials in one vial. Published studies have investigated GHK-Cu in fibroblast and extracellular-matrix models, BPC-157 in preclinical tendon and tissue models, and thymosin beta-4 in cell-migration and wound-repair models. These studies concern individual materials under their authors’ experimental conditions. They are not evidence for the performance, interactions or suitability of this exact combined formulation.

TB-500 is a research-market designation. Literature concerning thymosin beta-4 provides related scientific context but should not be treated as proof that every material sold under the TB-500 name is chemically identical. Use the applicable batch documentation when assessing component identity.

Batch documentation

Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the product, stated composition and batch identifier to the corresponding report before relying on any result.

View available GLOW lab results →

Supply and laboratory handling

  • Supplied as a single vial containing the component amounts stated above.
  • Keep the sealed lyophilised vial dry and protected from direct light.
  • A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, component-specific information and your laboratory’s validated procedure.
  • Use clean laboratory technique and equipment appropriate to the intended analytical method.
  • Follow the lot-specific documentation and your laboratory’s validated handling and storage procedures.
  • Avoid repeated temperature cycling and unnecessary exposure to moisture.

Where a batch document or supplier specification gives different instructions, the lot-specific document takes precedence.

Frequently asked questions

What does the GLOW blend contain?

Each 70mg vial is labelled as containing GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg.

Has this exact blend been studied?

The references provided in the Research tab concern the individual named components or related research material. No published study of this exact three-component formulation is cited, and component findings should not be assumed to describe the combined blend.

Which vial sizes are available?

Current vial sizes, stock, pre-order status, pricing and any batch-documentation indicators are shown in the variation selector above.

Does every batch have a published laboratory result?

No. Results are available only for the selected batches marked with a result indicator. Always check that the product, composition and batch identifier match the report.

How should the material be stored?

Keep the sealed lyophilised blend dry and protected from light. A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, component-specific information and your laboratory’s validated procedure. Avoid repeated temperature cycling and moisture exposure. No universal shelf-life is stated unless it is supported by batch documentation.

Information reviewed: 29 August 2026.

Size

70mg

Batch-specific analytical documentation

Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.

  • Result available: a published report is available for the marked variation.
  • Test pending: a sample has been submitted, but no completed result is being claimed.
  • No indicator: no product-specific result is currently displayed for that variation.

Check the identifiers

Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.

Browse published lab results →

Storage and stability

Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.

Form Suggested storage Important note
Sealed lyophilised material Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling.
Reconstituted solution Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed.

No universal shelf-life is claimed

Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.

Component research

GLOW is a combined research blend. The sources below concern its individual named components under the materials and conditions used by the cited authors. They are not studies of this exact 50mg GHK-Cu / 10mg BPC-157 / 10mg TB-500 formulation and do not establish the identity, purity, performance or suitability of any material sold on this page.

  1. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988. GHK-Cu component context. View on PubMed ↗
  2. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003. BPC-157 component context. View on PubMed ↗
  3. Malinda KM et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999. Thymosin beta-4 research context associated with the TB-500 component designation. View on PubMed ↗

Component literature is not blend or batch evidence

No study of this exact three-component GLOW formulation is cited. TB-500 is a research-market designation; the linked paper concerns thymosin beta-4 and must not be treated as proof that every material sold under the TB-500 name is identical. Confirm component identity against the applicable batch documentation.